Stock listing
Enliven Therapeutics, Inc.
Selected listing: ELVN · NASDAQ · USD · US
Enliven Therapeutics, Inc. (NASDAQ:ELVN), Health Technology. Latest release Oct 6, 2026: Enliven Therapeutics Announces FDA Alignment on ENABLE-2 Phase 3…
- Ticker
- NASDAQ:ELVN
- Asset type
- Stock
- Sector
- Health Technology
- Industry
- Biotechnology
- Exchange
- NASDAQ
- Currency
- USD
About Enliven Therapeutics, Inc.
Enliven Therapeutics, Inc. (ticker: ELVN) is a public company based in the United States, specializing in innovative therapeutic solutions. The company is committed to developing effective treatments and improving patient outcomes in the healthcare sector.
Latest news from Enliven Therapeutics, Inc.
Enliven Therapeutics Announces FDA Alignment on ENABLE-2 Phase 3 Trial Design for Relcobatinib (ELVN-001) in Previously Treated Chronic Myeloid Leukemia
October 6, 2026
Enliven Therapeutics Announces Oral and Poster Presentations at the Society of Hematologic Oncology (SOHO) 2026 Annual Meeting
August 31, 2026
Elevar Therapeutics Receives FDA Complete Response Letter for Combination of Rivoceranib and Camrelizumab as a First-line Treatment for Unresectable or Metastatic Hepatocellular Carcinoma
July 10, 2026
Enliven Therapeutics Announces Closing of Upsized Public Offering of Common Stock and Pre-Funded Warrants and Full Exercise of the Underwriters' Option to Purchase Additional Shares
June 15, 2026
Enliven Therapeutics Announces Updated Positive Phase 1 Clinical Data and Alignment with FDA on Key Phase 3 Trial Design Components
June 11, 2026
Events
Research Enliven Therapeutics, Inc.
Enliven Therapeutics, Inc. company profile
View the public company page for Enliven Therapeutics, Inc. on 6ix.
Enliven Therapeutics, Inc. news
Read company news and market updates connected to Enliven Therapeutics, Inc..
Enliven Therapeutics, Inc. investor events
Find investor webinars, events, and replay context for Enliven Therapeutics, Inc..